Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 16/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891335 | 0.85 | NR1H4 (0.49) | GPBAR1PRKCDNR1H4 | |
| SCHEMBL9891334 | 0.85 | NR1H4 (0.49) | GPBAR1PRKCDNR1H4 | |
| SCHEMBL9891264 | 0.84 | PRKCD (0.45) | GPBAR1PRKCDNR1H4 | |
| SCHEMBL15800098 | 0.84 | GPBAR1 (0.47) | GPBAR1PRKCDNR1H4 | |
| SCHEMBL16512194 | 0.84 | GPBAR1 (0.47) | GPBAR1PRKCDNR1H4 | |
| SCHEMBL9891261 | 0.84 | GPBAR1 (0.57) | GPBAR1PRKCDNR1H4 | |
| SCHEMBL9891262 | 0.80 | GPBAR1 (0.79) | GPBAR1PRKCDNR1H4 | |
| SCHEMBL16995383 | 0.78 | GPBAR1 (0.66) | GPBAR1PRKCDNR1H4 | |
| SCHEMBL9891336 | 0.77 | GPBAR1 (0.57) | GPBAR1PRKCD | |
| SCHEMBL19633129 | 0.76 | SLC10A1 (0.39) | GPBAR1PRKCDNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802661-B2 | C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | ERG28, BET1, BRD3 | GPBAR1 2177/4885PRKCD 2347/4885NR1H4 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.